Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686920 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
A Phase 3 study of Hepatic Encephalopathy, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 322
- Enrollment target
- 20
- Study locations
NCT00686920: Completed Phase 3 study of Hepatic Encephalopathy, sponsored by Bausch Health Americas.
NCT00686920 is a Phase 3 study of Hepatic Encephalopathy that has completed, run by Bausch Health Americas. The registered enrollment target is 322 participants, above the 150-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (115% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00686920, a Phase 3 study of Hepatic Encephalopathy, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 322 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
Primary Outcome
A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Conditions Studied
Interventions
- DRUG Rifaximin
Study Locations (20)
California
- - Aurora
- - Fresno
- - La Jolla
- - Long Beach
- - Los Angeles
- - Merced
- - Sacramento
- - San Francisco
New York
- - Bayside
- - New York
Alabama
- - Birmingham
Colorado
- - Golden
District of Columbia
- - Washington D.C.
Georgia
- - Macon
Iowa
- - Iowa City
Louisiana
- - Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2007-03-07 |
| Est. Completion | 2010-12-08 |
| Phase | Phase 3 |
What the finished NCT00686920 record still lists
NCT00686920 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, above the 150-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (115% higher).
The record links to 1 condition, with Hepatic Encephalopathy appearing as the primary indexed condition, and to 1 intervention - of which Rifaximin is the first listed.
NCT00686920 names 20 study sites across 12 states, led by California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT00686920 about?
NCT00686920 is a clinical study titled "Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy". This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
What is the current status of trial NCT00686920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 322 participants. The study started on 2007-03-07. Estimated completion is 2010-12-08.
What conditions does trial NCT00686920 study?
This clinical trial studies the following conditions: Hepatic Encephalopathy.
What interventions are being tested in trial NCT00686920?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT00686920?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00686920 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00686920's enrollment target sits among peer trials
322 3rd of 12 higher than 10 of 12 other Hepatic Encephalopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Encephalopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
ACTIVE NOT RECRUITING · Phase 3
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
RECRUITING · NA
-
TReatment for ImmUne Mediated PathopHysiology
RECRUITING · Phase 2
-
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI